Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics (NASDAQ: DMRA) granted equity awards to five newly hired, non-executive employees on November 1, 2026, as employment inducements.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Damora Therapeutics (NASDAQ: DMRA) granted equity awards to five newly hired, non-executive employees on November 1, 2026, as employment inducements. The awards comprise options to purchase 120,900 ordinary shares at an exercise price of $21.49 per share, with a 10-year term.
The options vest 25% on the first anniversary of each employee’s start date, followed by equal monthly installments over 36 months. The independent Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4), subject to the 2022 Inducement Plan and option award agreements.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options for 120,900 ordinary shares at $21.49 per share create potential dilution if exercised.
Key Figures
- Options granted
- 120,900 ordinary shares
- Aggregate inducement grants
- Exercise price
- $21.49 per share
- Inducement options
- Option term
- 10 years
- Inducement options
- Initial vesting
- 25%
- On the first anniversary of employees' start dates
- Subsequent vesting period
- 36 months
- Equal monthly installments after initial vesting
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on November 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants consist of options to purchase an aggregate of 120,900 Damora ordinary shares with a 10-year term and an exercise price of
About Damora Therapeutics
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.
Investor/Media Contact:
Jim Baker
Chief Corporate Affairs Officer
Investors: investors@damoratx.com
Media: media@damoratx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.